Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2 Bromolysergic Acid Diethylamide
2. 2-bromolysergic Diethylamide
3. Bol
4. Bol 148
5. Bromo-lsd
1. Bromolysergide
2. 2-bromo-lsd
3. 478-84-2
4. Bol-148
5. Bromo-lsd
6. Jua77qeu32
7. Chembl274384
8. Bromlysergamide
9. Ergoline-8-carboxamide, 2-bromo-9,10-didehydro-n,n-diethyl-6-methyl-, (8beta)-
10. Bromolysergic Acid Diethylamide
11. D-2-bromolysergic Acid Diethylamide
12. 2-bromo-d-lysergic Acid Diethylamide
13. Brom Lsd
14. (6ar,9r)-5-bromo-n,n-diethyl-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide
15. 2-br-lsd
16. Usaf Sz-1
17. 2-brom-d-lysergic Acid Diethylamine
18. Lsd,2-bromo
19. D-2-brom-diethylamide Of Lysergic Acid
20. Unii-jua77qeu32
21. Bromolysergide [mi]
22. Gtpl272
23. Bol148
24. Schembl1883414
25. Dtxsid30878496
26. Bdbm50130269
27. Zinc13531276
28. 2-bromo-9,10-didehydro-n,n-diethyl-6-methylergoline-8-beta-carboxamide
29. 9,10-didehydro-n,n-diethyl-2-bromo-6-methylergoline-8-beta-carboxamide
30. Ergoline-8-beta-carboxamide, 2-bromo-9,10-didehydro-n,n-diethyl-6-methyl-
31. 2-bromo-n,n-diethyl-d-lysergamide
32. Q4596865
33. (8beta)-2-bromo-9,10-didehydro-n,n-diethyl-6-methylergoline-8-carboxamide
34. (6ar,9r)-5-bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic Acid Diethylamide
35. 5-bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic Acid Diethylamide
| Molecular Weight | 402.3 g/mol |
|---|---|
| Molecular Formula | C20H24BrN3O |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 401.11027 g/mol |
| Monoisotopic Mass | 401.11027 g/mol |
| Topological Polar Surface Area | 39.3 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 561 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Bromolysergide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bromolysergide, including repackagers and relabelers. The FDA regulates Bromolysergide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bromolysergide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bromolysergide supplier is an individual or a company that provides Bromolysergide active pharmaceutical ingredient (API) or Bromolysergide finished formulations upon request. The Bromolysergide suppliers may include Bromolysergide API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bromolysergide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bromolysergide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bromolysergide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bromolysergide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bromolysergide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bromolysergide suppliers with NDC on PharmaCompass.
Bromolysergide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bromolysergide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bromolysergide GMP manufacturer or Bromolysergide GMP API supplier for your needs.
A Bromolysergide CoA (Certificate of Analysis) is a formal document that attests to Bromolysergide's compliance with Bromolysergide specifications and serves as a tool for batch-level quality control.
Bromolysergide CoA mostly includes findings from lab analyses of a specific batch. For each Bromolysergide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bromolysergide may be tested according to a variety of international standards, such as European Pharmacopoeia (Bromolysergide EP), Bromolysergide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bromolysergide USP).
LOOKING FOR A SUPPLIER?
